object
investig
safeti
risk
efficaci
benefit
echinacea
purpurea
extract
prevent
common
cold
episod
larg
popul
period
method
healthi
subject
alloc
receiv
either
alcohol
extract
freshli
harvest
e
purpurea
herba
root
placebo
particip
requir
record
advers
event
rate
coldrel
issu
diari
throughout
investig
period
nasal
secret
sampl
acut
cold
screen
virus
result
total
advers
event
occur
echinacea
placebo
treatment
nine
particip
experienc
advers
event
least
possibl
relat
studi
drug
advers
drug
reaction
thu
safeti
echinacea
noninferior
placebo
echinacea
reduc
total
number
cold
episod
cumul
episod
day
within
group
painkil
medic
episod
echinacea
inhibit
viral
confirm
cold
especi
prevent
envelop
viru
infect
p
echinacea
show
maxim
effect
recurr
infect
prevent
effect
increas
therapi
complianc
adher
protocol
conclus
compliant
prophylact
intak
e
purpurea
period
appear
provid
posit
risk
benefit
ratio
common
cold
recogn
frequent
diseas
western
civil
number
one
caus
primari
health
care
consult
cost
ill
associ
noninfluenza
infect
estim
billion
usd
includ
direct
indirect
cost
addit
cost
ill
caus
influenza
upper
respiratori
tract
infect
present
seriou
burden
human
economi
cold
compris
syndrom
symptom
typic
nasal
complaint
cough
sore
throat
sometim
constitut
complaint
like
headach
malais
fever
symptom
typic
selflimit
repres
reaction
infect
rhino
corona
adeno
respiratori
syncyti
para
influenza
viru
develop
effect
cold
prevent
hamper
multipl
virus
complex
interplay
host
viru
decad
intens
research
focus
applic
broadspectrum
antivir
like
interferon
capsid
bind
protein
solubl
receptor
direct
rhinovir
infect
andor
replic
therapi
show
efficaci
clinic
induc
infect
fail
significantli
prevent
cold
larger
field
studi
includ
multipl
type
respiratori
virus
nasal
applic
interferon
show
good
prevent
efficaci
typic
accompani
advers
reaction
like
nasal
bleed
vaccin
present
effect
method
manag
season
influenza
respiratori
syncyti
viru
rsv
children
howev
efficaci
vaccin
depend
immunolog
fit
recipi
primarili
evidencebas
complementari
altern
medicin
older
individu
chronic
heart
diseas
insuffici
immun
built
result
reduc
immun
vulner
popul
anoth
method
prevent
cold
infect
modul
immun
system
context
echinacea
play
import
therapeut
role
sever
decad
echinacea
use
prevent
cold
flu
despit
worldwid
accept
limit
data
avail
prophylact
efficaci
longterm
clinic
trial
studi
spontan
cold
conduct
schoeneberg
schmidt
schenk
cohen
et
al
melchart
et
al
report
mix
result
three
studi
artifici
induc
rhinoviru
infect
show
trend
toward
prevent
symptomat
cold
episod
echinacea
gener
prophylact
benefit
reach
signific
data
pool
metaanalysi
singl
studi
tend
small
sampl
size
undefin
low
statist
power
hand
good
safeti
profil
mandatori
therapi
design
taken
sever
month
consid
mildtomoder
natur
common
cold
potenti
prevent
therapi
must
induc
minim
safeti
risk
produc
posit
risk
benefit
ratio
predomin
absenc
side
effect
suffici
import
differ
expect
cold
treatment
like
vitamin
herbal
extract
present
studi
aim
examin
safeti
paramet
e
purpurea
longterm
treatment
studi
design
also
investig
efficaci
profil
predefin
primari
variabl
efficaci
appropri
sampl
size
base
power
calcul
overal
studi
repres
largest
clinic
trial
ever
perform
test
safeti
efficaci
echinacea
extract
first
studi
employ
viru
screen
techniqu
studi
random
doubleblind
parallel
placebocontrol
clinic
trial
conduct
common
cold
center
cardiff
univers
unit
kingdom
studi
conduct
accord
declar
helsinki
intern
confer
harmon
good
clinic
practic
regul
associ
british
pharmaceut
industri
human
tissu
author
trial
receiv
ethic
approv
local
ethic
committe
juli
final
medicin
healthcar
product
regulatori
agenc
mhra
juli
studi
regist
eudract
number
octob
novemb
healthi
particip
includ
studi
randomli
alloc
receiv
either
e
purpurea
extract
placebo
inclus
visit
everi
particip
receiv
medic
cover
month
treatment
diari
daili
record
advers
reaction
unusu
unexpect
symptom
today
presenc
sever
coldrel
symptom
use
concurr
medic
particip
return
month
studi
center
return
unus
medic
complet
diari
check
complianc
complet
return
diari
new
treatment
diari
issu
anoth
month
accept
amend
studi
protocol
also
hand
three
kit
selfcollect
nasal
secret
acut
cold
episod
kit
contain
midturbin
nasal
swab
suitabl
selfcollect
vial
contain
univers
transport
medium
storag
room
temperatur
copan
brescia
itali
bag
safe
transport
sampl
daklapack
oberhausen
germani
echinacea
product
commerci
avail
echinaforc
drop
produc
vogel
bioforc
ag
switzerland
echinaforc
prepar
alcohol
mm
extract
freshli
harvest
e
purpurea
combin
herba
der
root
der
sampl
microbiolog
test
proven
free
endotoxin
batch
use
studi
standard
contain
g
dodecatetraeno
acid
isobutylamid
base
highperform
liquid
chromatographi
measur
placebo
drop
similar
shape
color
consist
odor
flavor
contain
amount
alcohol
liquid
aliquot
amber
bottl
close
screw
cap
attach
integr
calibr
syring
accur
dose
mldose
primari
secondari
packag
ident
verum
placebo
therapi
regimen
accord
recommend
manufactur
particip
swallow
ml
per
day
ill
prevent
correspond
mg
extract
per
day
acut
stage
cold
particip
instruct
increas
dose
ml
per
day
total
daili
dose
mg
extract
singl
dose
dilut
water
retain
mouth
applic
method
expect
provid
maximum
local
antivir
effect
complianc
assess
monthli
visit
weigh
return
bottl
adher
recommend
dose
calcul
base
total
prophylact
acut
dose
record
diari
overal
method
administr
reflect
tradit
use
e
purpurea
provid
accur
echinaforc
dose
particip
recruit
via
advertis
around
univers
campu
first
contact
respond
receiv
infoleaflet
describ
trial
studi
inclus
criteria
adult
year
old
good
physic
condit
experienc
cold
per
year
exclus
criteria
ineffect
contracept
particip
anoth
studi
women
pregnant
breast
feed
current
cold
infect
current
take
antimicrobi
antivir
medic
alcohol
drug
abus
psychiatr
disord
epilepsi
attempt
suicid
plan
surgic
intervent
seriou
chronic
diseas
could
influenc
absorpt
metabol
elimin
medic
known
aid
autoimmun
diseas
diabet
type
corticosteroidtr
asthma
medicin
evidencebas
complementari
altern
medicin
treat
atopi
allergi
known
allergi
plant
composit
famili
asteracea
volunt
clinic
relev
laboratori
abnorm
drop
inclus
particip
provid
sign
inform
consent
total
subject
includ
subject
randomli
alloc
receiv
treatment
placebo
random
code
prepar
blocksiz
rancod
profession
program
particip
receiv
treatment
base
hisher
identif
number
alloc
accord
time
point
inclus
drug
person
dispens
investig
personnel
author
investig
random
procedur
prepar
statistician
origin
random
code
retain
statistician
seal
envelop
one
copi
convey
investig
case
emerg
investig
permit
open
envelop
contain
identif
treatment
blind
studi
treatment
found
adequ
pretest
test
person
treatment
group
nearli
half
particip
believ
given
echinaforc
prepar
subject
placebo
subject
verum
total
recipi
placebo
verum
state
know
prepar
given
least
evalu
subject
group
assum
proport
individu
advers
drug
reaction
adr
within
group
upper
limit
observ
onesid
confid
interv
differ
placebo
proport
echinaforc
proport
expect
less
power
assum
dropout
rate
particip
would
follow
studi
per
protocol
entir
month
treatment
estim
subject
would
requir
inclus
studi
cumul
episod
day
echinaforc
group
anticip
prophylact
effect
result
episod
day
placebo
group
studi
suffici
statist
power
show
prophylact
benefit
p
entir
studi
period
particip
retain
diari
record
ae
answer
question
unusu
unexpect
symptom
today
moreov
monthli
studi
visit
particip
interview
acut
experienc
event
studi
physician
ae
analysi
includ
ae
datetim
onset
start
date
studi
treatment
analysi
exclud
ae
datetim
onset
occur
start
date
inform
datetim
onset
miss
ae
code
lowest
level
term
latest
instal
version
meddra
dictionari
v
ae
describ
physician
lowest
level
term
chosen
best
match
physician
actual
descript
lowest
level
term
translat
prefer
term
pt
classifi
system
organ
class
soc
employ
latest
instal
version
meddra
dictionari
v
primari
analysi
perform
basi
per
protocol
popul
inclus
exclus
visit
particip
provid
blood
sampl
process
determin
clinic
chemistri
hematolog
paramet
differenti
blood
cell
count
clinic
relev
abnorm
deviat
normal
rang
flag
laboratori
final
safeti
criterion
assess
particip
physician
therapi
toler
causal
relationship
record
ae
studi
medic
rate
physician
either
relat
unlik
possibl
probablelik
certain
assessableunclassifi
unknown
applic
ae
least
possibl
relat
medic
consid
advers
drug
reaction
adr
includ
primari
analysi
per
protocol
collect
pp
respect
proport
patient
adr
compar
group
determin
noninferior
treatment
prove
safeti
less
noninferior
limit
differ
proport
patient
adr
echinaforc
placebo
group
altern
hypothesi
ha
interest
show
noninferior
determin
proport
patient
adr
echinaforc
group
would
lower
proport
patient
adr
placebo
group
plu
delta
ie
ha
altern
hypothesi
accept
upper
confid
limit
twosid
differ
proport
echinaforc
placebo
lower
delta
studi
delta
correspond
occurr
ae
secondari
safeti
variabl
deduc
safeti
collect
second
question
particip
answer
diari
believ
cold
today
answer
ye
acut
cold
symptom
headach
chilli
sneez
nasal
obstruct
nasal
discharg
sore
throat
cough
malais
rate
likert
scale
entri
absenc
mild
moder
sever
symptom
addit
particip
indic
diari
daili
intak
concomit
medic
andor
therapi
matrix
base
work
jackson
colleagu
describ
clinic
featur
symptom
viral
induc
common
cold
definit
current
accept
valid
method
differenti
cold
isol
symptom
like
hay
fever
allergi
develop
clinic
pictur
cold
thu
cold
episod
defin
minim
total
symptom
score
sum
consecut
day
particip
believ
cold
andor
report
rhinorrhea
last
day
set
three
predefin
prophylact
variabl
analyz
confirmatori
manner
total
number
cold
episod
cumul
episod
day
comed
cold
episod
three
paramet
analyz
individu
chisquar
test
determin
whether
ratio
evidencebas
complementari
altern
medicin
cumul
event
ie
cold
episod
treatment
group
correspond
ratio
underli
group
sampl
primari
efficaci
analysi
focus
episod
durat
day
occur
intent
treat
itt
popul
nullhypothesi
reject
chisquar
statist
result
p
valu
likewis
incid
recurr
infect
whole
group
compar
underli
group
sampl
chisquar
statist
analysi
primari
analysi
prevent
efficaci
agreement
earlier
work
schmidt
schenk
tiralongo
nasal
secret
collect
acut
stage
cold
sampl
insert
transport
vial
store
studi
site
c
end
clinic
trial
sampl
analyz
presenc
respiratori
virus
statist
analys
perform
sa
system
version
testim
idv
datenanalys
und
versuchsplanung
total
studi
subject
screen
alloc
one
treatment
group
octob
novemb
subject
complet
studi
last
patient
visit
conduct
late
april
eightytwo
subject
discontinu
trial
prematur
contact
random
withdrew
consent
termin
studi
due
technic
reason
termin
due
intoler
ae
deterior
particip
health
withdrew
document
reason
complet
flow
diagram
particip
disposit
shown
figur
two
group
compar
regard
age
gender
bodi
weight
height
bodi
mass
index
bmi
notic
differ
group
anamnest
variabl
includ
blood
pressur
heart
rate
variabl
significantli
differ
group
suscept
cold
measur
number
cold
experienc
past
particip
placebo
group
significantli
less
suscept
infect
echinacea
group
p
fisher
exact
test
see
tabl
percentag
differ
upper
limit
onesid
confid
interv
less
consequ
echinaforc
demonstr
noninferior
placebo
incid
adr
per
protocol
popul
total
ae
report
subject
treat
echinaforc
ae
report
subject
placebo
group
safeti
collect
four
ae
echinaforc
group
placebo
group
led
discontinu
treatment
tabl
sever
ae
observ
echinaforc
one
sever
ae
glandular
fever
occur
placebo
requir
hospit
overal
signific
differ
could
identifi
occurr
ae
group
whether
relat
unrel
studi
drug
fisher
exact
test
chang
consid
total
number
system
organ
class
prefer
term
data
shown
hematolog
biochem
measur
signific
clinic
relev
chang
echinaforc
treatment
comparison
placebo
detect
abnorm
found
exposur
echinaforc
previous
report
safeti
concern
like
induct
allerg
reaction
leucopenia
autoimmun
diseas
observ
echinacea
treatment
particip
echinaforc
group
placebo
group
assess
toler
medicin
good
good
signific
differ
group
efficaci
assess
concurr
safeti
variabl
longterm
treatment
echinaforc
priori
case
definit
made
sampl
size
calcul
statist
methodolog
measur
probabl
clinic
end
point
placebo
group
total
cold
episod
collect
durat
episod
day
comparison
echinaforc
group
episod
collect
durat
episod
day
itt
popul
differ
cumul
event
episod
episod
day
treatment
group
reach
statist
signific
episod
day
p
chisquar
test
total
recur
infect
observ
particip
echinacea
episod
subject
placebo
treatment
differ
reach
statist
signific
well
p
chisquar
test
concurr
medic
signific
factor
present
studi
echinacea
placebo
group
episod
respect
treat
aspirin
paracetamol
ibuprofen
thu
significantli
cold
episod
placebo
group
addit
treat
pain
medic
p
chisquar
test
median
painkil
medic
cold
episod
echinaforc
group
placebo
group
total
nasal
secret
sampl
collect
studi
echinacea
group
placebo
group
differ
borderlin
signific
p
chisquar
test
sampl
presenc
respiratori
viru
confirm
throughout
whole
studi
period
viral
infect
detect
echinaforc
treat
group
detect
placebo
group
intriguingli
strongest
effect
seen
membran
virus
like
corona
influenza
parainfluenza
respiratori
syncytialand
metapneumoviru
detect
infect
two
group
p
chisquar
test
total
recur
viral
infect
occur
echinacea
ic
placebo
longterm
studi
month
complianc
repres
sensibl
factor
therefor
specif
examin
popul
took
recommend
studi
medic
entir
studi
period
eightyeight
compliant
subject
echinacea
group
report
infect
episod
day
comparison
placebo
group
episod
report
episod
day
repres
differ
number
episod
day
despit
low
denomin
differ
highli
statist
signific
p
chisquar
test
similar
effect
observ
group
compliant
document
ie
report
least
one
ae
andor
one
cold
symptom
diari
month
howev
analys
explor
natur
serv
substanti
prevent
effect
echinacea
compliant
group
moreov
compliant
group
less
affect
confound
prevent
mildtomoder
diseas
like
common
cold
requir
therapi
satisfactori
safeti
efficaci
profil
common
cold
particularli
need
prevent
treatment
due
high
frequenc
high
associ
cost
ill
assum
typic
adult
spend
year
lifetim
cold
symptom
despit
preval
substanti
research
effort
past
specif
prevent
treatment
develop
date
toler
safeti
profil
use
long
term
present
studi
safeti
efficaci
variabl
analyz
collect
total
week
month
prophylaxi
subject
use
highli
sensit
method
detect
ae
includ
physician
experi
assess
causal
adr
addit
extens
laboratori
test
conduct
examin
hematolog
metabol
paramet
overal
safeti
profil
echinaforc
good
base
total
ae
adr
laboratori
measur
within
treatment
group
comparison
placebo
addit
global
toler
assess
physician
particip
quit
posit
fact
mention
would
take
medicin
indic
treatment
echinaforc
well
accept
although
present
data
indic
safeti
concern
echinacea
larg
popul
extend
period
time
fulli
exclud
possibl
rare
rare
advers
event
data
studi
also
assess
cold
episod
use
highli
accept
method
develop
jackson
et
al
studi
design
larg
enough
show
prevent
efficaci
suffici
power
employ
predefin
valid
case
definit
sampl
size
calcul
statist
methodolog
measur
probabl
accord
confirmatori
approach
statist
signific
differ
echinacea
placebo
found
cumul
cold
episod
day
comed
episod
overal
expect
cold
episod
observ
cold
episod
although
treatment
effect
number
cold
episod
cumul
episod
day
statist
power
insuffici
detect
signific
differ
group
paramet
differ
group
openfield
longterm
prevent
studi
compar
previou
studi
effect
nasal
administ
interferon
differ
consid
clinic
relev
present
studi
two
covari
confound
report
outcom
significantli
first
particip
echinacea
group
higher
suscept
cold
placebo
group
second
particip
echinacea
group
report
less
frequent
use
classic
pain
medic
also
chlorphenamin
codeinecocodamol
pseudoephedrin
adjust
covari
would
like
result
even
higher
effect
closer
result
report
viral
analys
subgroup
share
similar
anamnest
condit
previou
studi
describ
problem
associ
assess
cold
infect
pure
subject
symptomat
ground
therefor
aim
substanti
data
viru
analys
nasal
secret
virus
success
detect
via
revers
transcriptas
polymeras
chain
reaction
rtpcr
sampl
difficult
draw
conclus
specif
virus
due
low
overal
number
sampl
therefor
aim
confirm
previou
vitro
data
show
echinacea
strong
antivir
effect
membran
virus
inde
upon
pool
incid
influenza
parainfluenza
rsv
metapneumoviru
coronavirus
found
total
infect
placebo
group
infect
echinacea
group
p
chisquar
test
individu
reduct
infect
depend
respect
viru
type
result
fulli
consist
previou
studi
pleschka
et
al
demonstr
similar
antivir
effect
prepar
use
present
studi
present
work
describ
largest
clinic
trial
date
test
safeti
efficaci
echinacea
investig
riskbenefit
longterm
treatment
prophylact
treatment
echinaforc
month
appear
benefici
mani
reason
first
echinaforc
show
advantag
safeti
profil
induc
health
risk
report
placebo
treatment
second
prolong
treatment
echinaforc
associ
signific
therapeut
benefit
overal
riskbenefit
result
clinic
studi
suggest
longterm
treatment
e
purpurea
month
recommend
